vrc-ebomab092-00-ab
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started May 16, 2018 (NCT03478891)
Timeline
Indications
Mechanism of action
- EbolavirusImmunity, passive
Ebolavirus immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03719586 | Phase 2/Phase 3 (Phase 3) | Nov 20, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03478891 | Phase 1 | May 16, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1